Showing 5741-5750 of 7115 results for "".
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof
- ODAC and JDD Honor Dr. Joel L. Cohenhttps://practicaldermatology.com/news/odac-and-jdd-honor-dr-joel-l-cohen/2461040/The ODAC Dermatology, Aesthetic & Surgical Conference, in partnership with the Journal of Drugs in Dermatology (JDD), honored Joel L. Cohen, MD, with the 2022 Outstanding Leadership in Dermatology Educa
- Vial to Host Advisory Boardhttps://practicaldermatology.com/news/vial-to-host-advisory-board/2461038/Vial is hosting an Advisory Board with leading research sites to discuss the challenges in clinical research. Launched in conjunction with the 2022 Winter Clinical Dermatology conference, the meeting will focus on improving speed and quality of trials in dermatology. The Vial executive
- Dermatologists Seeing High Rates of Hair Loss after COVID-19https://practicaldermatology.com/news/dermatologists-seeing-high-rates-of-hair-loss-after-covid-19/2461034/When Paula Diaz contracted COVID, she expected to lose her sense of smell and taste but not her hair. “I spent six days in the hospital being treated for the virus and several weeks after I came home, my hair started falling out in clumps,” says Paula, who added that s
- $511M SPAC Deal for Sunevahttps://practicaldermatology.com/news/511m-spac-deal-for-suneva/2461032/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Drug Combination Boosts Progression-free Survival in Advanced Melanomahttps://practicaldermatology.com/news/drug-combination-boosts-progression-free-survival-in-advanced-melanoma/2461027/Combining relatlimab and nivolumab (Opdivo) may double progression-free survival in patients with advanced melanoma, according to a new study in the New England Journal of Medicine. Relatlimab, which blocks
- The American Skin Association Re-ups Support for the SPOTS Programhttps://practicaldermatology.com/news/the-american-skin-association-re-ups-support-for-the-spots-program/2461023/The American Skin Association (ASA) is renewing its support for the SPOTS (Sun Protection Outreach Teaching by Students) program. SPOTS is a public health outreach educational program aimed at both elementary school students and young teenagers. The comprehensive pr
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k
- Otezla Becomes First Oral Psoriasis Treatment Approved Across All Disease Severitieshttps://practicaldermatology.com/news/otezla-becomes-first-oral-psoriasis-treatment-approved-across-all-disease-severities/2461014/Otezla® (apremilast) from Amgen is now approved for the treatment of adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. This expanded indication makes Otezla the first and only oral treatment approved 
- Rinvoq Scores FDA Nod for Active Psoriatic Arthritishttps://practicaldermatology.com/news/rinvoq-scores-us-fda-nod-for-active-psoriatic-arthritis/2461012/The U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib; 15 mg, once daily) for the treatment of adults with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. "The efficacy